Increased Serum Level of Cyclopropaneoctanoic Acid 2-Hexyl in Patients with Hypertriglyceridemia-Related Disorders

Adriana Mika¹ · Piotr Stepnowski¹ · Michal Chmielewski² · Sylwia Małgorzewicz³ · Lukasz Kaska⁴ · Monika Proczko⁴ · Krzysztof Ratnicki-Sklucki⁴ · Maciej Sledzinski⁵ · Tomasz Sledzinski⁶

Received: 15 September 2015 / Accepted: 7 March 2016 / Published online: 22 March 2016
© The Author(s) 2016. This article is published with open access at Springerlink.com

Abstract We recently reported the presence of various cyclopropane fatty acids—among them, cyclopropaneoctanoic acid 2-hexyl—in the adipose tissue of obese women. The aim of this study was to verify whether the presence of cyclopropaneoctanoic acid 2-hexyl in human serum was associated with obesity or chronic kidney disease (both being related to dyslipidemia), and to find potential associations between the serum level of this compound and specific markers of these conditions. The serum concentration of cyclopropaneoctanoic acid 2-hexyl was determined by gas chromatography–mass spectrometry (GC–MS) in non-obese controls, obese patients, obese patients after a 3-month low-calorie diet, and individuals with chronic kidney disease. Obese patients and those with chronic kidney disease presented with higher serum levels of cyclopropaneoctanoic acid 2-hexyl than controls. Switching obese individuals to a low-calorie (low-lipid) diet resulted in a reduction in this fatty acid concentration to the level observed in controls. Cyclopropaneoctanoic acid 2-hexyl was also found in foods derived from animal fat. Serum concentrations of triacylglycerols in the analyzed groups followed a pattern similar to that for serum cyclopropaneoctanoic acid 2-hexyl, and these variables were positively correlated with each other among the studied groups. Patients with hypertriglyceridemia-related conditions presented with elevated serum levels of cyclopropaneoctanoic acid 2-hexyl. Our findings suggest that its high serum level is related to high serum triacylglycerol concentrations rather than to body mass or BMI.

Keywords Cyclopropaneoctanoic acid 2-hexyl · Obesity · Chronic kidney disease · Hypertriglyceridemia

Abbreviations
BMI Body mass index
GC–MS Gas chromatography–mass spectrometry
CFA Cyclopropane fatty acid
FA Fatty acid
CPOA2H Cyclopropaneoctanoic acid 2-hexyl
SFA Saturated fatty acid
MUFA Monounsaturated fatty acid
PUFA Polyunsaturated fatty acid
CKD Chronic kidney disease
FAME Fatty acid methyl ester
SEM Standard error of the mean
TAG Triacylglycerol

Introduction
Cyclopropane fatty acids (CFA) are found in phospholipids and glycolipids of cell membranes from many bacterial
species, and likely play a role in the pathogenesis of bacterial infections [1]. These fatty acids (FA) have also been found in certain eukaryotes, including protozoa [2] and plants [3, 4]. However, few studies have documented the presence of CFA in animals [5–7]. We recently found four CFA—cyclopropanoenoic acid 2-hexyl, cyclopropanoenoic acid 2-octyl, cyclopropanonenonoic acid and 2-[[2-[(2-ethylcyclopropyl)methyl]cyclopropyl]methyl] acid—in the adipose tissue of obese women [8]. Cyclopropanoenoic acid 2-hexyl (CPOA2H), also referred to as 9,10-methylene hexadecanoic acid, was the most abundant CFA, as well as the only CFA detectable in their serum [8].

The results of previous studies suggest that CFA may play an important role in the human body, given their regulatory properties such as control of cyclooxygenase activity [9], actomyosin ATPase [10], protein kinase C-ε [11], stearoyl-CoA desaturase [12] and inflammation [13]. CFA present in bacteria and plants are synthesized from unsaturated FA due to involvement of cyclopropane synthase, an enzyme catalyzing the addition of the methylene group from S-adenosylmethionine to the double bond of FA precursors [1, 14]. To date, however, this enzyme has not been identified in animals. Since our previous research [8] included adipose tissue and serum from obese women, we thought that it would be interesting to examine whether the presence of CFA was obesity-specific. To this end, we determined serum levels of CPOA2H in non-obese controls, obese patients, obese persons after a 3-month low-calorie diet and individuals with chronic kidney disease (CKD), i.e. with a disease related to dyslipidemia. We also looked for potential associations between the levels of CPOA2H, serum concentrations of lipids, and other biochemical and anthropometrical parameters of the study subjects.

Materials and Methods

Patients

The study included 76 women. Ten obese patients were examined at an ambulatory surgical facility as a part of the qualification for bariatric surgery performed at the Department of General, Endocrine and Transplant Surgery, Medical University of Gdansk (Poland). Another 29 obese patients were on a low-calorie diet (1000–1200 kcal/day, high protein and low fat and carbohydrate content) for 3 months prior to the study. The mean weight loss in this group was 9.75 kg. Patients with CKD are another population in whom dyslipidemia is a common finding. Although the etiology of lipid disorders observed in individuals with CKD is different from that in obese patients, the major disturbances, including elevated triacylglycerol concentration, are essentially similar. In addition, like obese subjects, patients with CKD present with clearly increased cardiovascular risk. Consequently, 15 women were selected from a pool of patients who had been subjected to peritoneal dialysis due to end-stage renal failure at the Department of Nephrology, Transplantology and Internal Medicine, Medical University of Gdansk. The control group included 22 healthy non-obese volunteers who were referred for an annual health check-up. The patients’ serum was obtained retrospectively from a sample bank, and clinical and demographic characteristics were extracted from a clinical database. The protocol of the study was approved by the local bioethics committee at the Medical University of Gdańsk (protocol nos. NKEBN/475/2012 and NKEBN/614/2013-2014), and patients gave their informed consent to use of their clinical data and analyses performed in the study. The study protocol adhered to the tenets of the Declaration of Helsinki of the World Medical Association.

Characteristics of the study participants are presented in Table 1. A Tanita scale was used to estimate the parameters of body constitution, including body weight, body height and BMI. BMI was calculated from the following formula: BMI (kg/m²) = body weight (kg)/body height (m)². Blood samples for determining basic laboratory parameters, such as serum albumin, C-reactive protein, total cholesterol, and triacylglycerols, were collected from patients after an overnight fast. All laboratory parameters were determined at the Central Clinical Laboratory, Medical University of Gdańsk. The remaining aliquots of serum were stored at −80 °C for fatty acid composition analysis.

Gas Chromatography–Mass Spectrometry (GC–MS) Analysis of FA

Total lipids were extracted from patient serum and from cow’s milk, porcine, chicken, trout fat, and rapeseed oil using the method described by Folch et al. [21]. Subsequently, FA were derivatized to FA methyl esters (FAME) using 10 % boron trifluoride-methanol solution. FA profiles in the adipose tissue and serum lipids were analyzed with the GCMS QP-2010SE unit (Shimadzu, Kyoto, Japan), as described previously [8]. In our recent study, we confirmed the identification of CPOA2H by derivatization of FA to picolinyl esters, followed by GC–MS analysis [8].

The presence of this FA in serum was further confirmed using a CPOA2H standard obtained from Matreya, LLC (State College, PA, USA). Concentrations of individual FA, including CPOA2H, were calculated based on the amount of added internal standard and volume of serum used for the procedure.

Statistical Analysis

The statistical significance of intergroup differences was determined with one-way analysis of variance (ANOVA),
and the Tukey post hoc test was used for multiple comparisons. Inter-group differences were considered significant at $p < 0.05$. All data are presented as means ± standard errors of the mean (SEM). Normality was verified with the Shapiro–Wilk test. The relationships between pairs of variables were determined on the basis of linear regression analysis. All calculations were conducted using SigmaPlot for Windows, version 11.0 (2008; Systat Software Inc).

**Results**

Obese subjects and CKD patients differed from the controls in terms of whole serum lipids FA concentrations. Obese women presented with higher serum concentrations of saturated FA (SFA) and monounsaturated FA (MUFA) (Table 2). Obese women after a low-calorie diet did not differ significantly from controls in terms of fatty acid concentrations (Table 2). Patients with chronic kidney disease presented with significantly lower n-6 PUFA levels than the controls (Table 2). Serum concentrations of CPOA2H were significantly higher in morbidly obese women than in non-obese subjects (24.2 ± 3.07 vs. 15.3 ± 1.69 µmol/L, $p < 0.05$; Fig. 1). Serum levels of CPOA2H in obese women after a low-calorie diet were similar to those found in the controls (16.7 ± 1.15 vs. 15.3 ± 1.69 µmol/L, $p < 0.05$; Fig. 1). CKD patients presented with significantly higher serum concentrations of CPOA2H than did controls (21.1 ± 1.92 vs 15.3 ± 1.69 µmol/L, $p < 0.05$; Fig. 1).

To identify the potential pathophysiological role of CPOA2H serum concentration, we also compared study groups in terms of selected anthropometric and biochemical parameters (Table 3). Since CPOA2H was originally found in serum from obese women [8], we first analyzed the BMI of our subjects. Both serum CPOA2H and BMI were significantly higher in morbidly obese women than in non-obese subjects (24.2 ± 3.07 vs. 15.3 ± 1.69 µmol/L, $p < 0.05$; Fig. 1). CKD patients presented with significantly higher serum concentrations of CPOA2H than did controls (21.1 ± 1.92 vs 15.3 ± 1.69 µmol/L, $p < 0.05$; Fig. 1).
Table 2  Fatty acid concentrations in the whole serum lipids of the study subjects

| Fatty acid | Controls (μmol/L) | Obese patients after diet (μmol/L) | Patients with chronic kidney disease (μmol/L) |
|-----------|-------------------|------------------------------------|-----------------------------------------------|
| 12:0      | 15.1 ± 1.54       | 24.2 ± 6.49                        | 16.4 ± 1.68                                   |
| 14:0      | 93.5 ± 9.04       | 188 ± 59.2*                        | 94.1 ± 7.29                                   |
| 15:0      | 26.1 ± 2.21       | 31.7 ± 6.03                        | 25.8 ± 1.71                                   |
| 16:0      | 1569 ± 125        | 2393 ± 482*                        | 1820 ± 92.7                                   |
| 17:0      | 23.4 ± 1.78       | 29.7 ± 5.91*                       | 21.7 ± 1.02                                   |
| 18:0      | 525 ± 42.2        | 668 ± 135                          | 491 ± 24.7                                    |
| 19:0      | 3.48 ± 0.32       | 3.73 ± 0.78                        | 3.08 ± 0.25                                   |
| 20:0      | 11 ± 0.84         | 15.8 ± 3.90                        | 11.2 ± 0.64                                   |
| 21:0      | 3.78 ± 0.34       | 3.65 ± 0.46                        | 4.31 ± 0.31                                   |
| 22:0      | 17.4 ± 1.12       | 19.6 ± 3.37                        | 18.2 ± 1.02                                   |
| 23:0      | 6.77 ± 0.54       | 7.38 ± 1.48                        | 6.57 ± 0.33                                   |
| 24:0      | 16.8 ± 1.09       | 18.1 ± 2.92                        | 17.1 ± 0.93                                   |
| SFA       | 2311 ± 14.9       | 3403 ± 57.7*                       | 2530 ± 10.3                                   |
| 14:1      | 4.74 ± 0.66       | 11.6 ± 4.6*                        | 4.76 ± 0.46                                   |
| 16:1      | 206 ± 21.7        | 386 ± 74.9*                        | 267 ± 22.1                                    |
| 18:1      | 1578 ± 132        | 2445 ± 470*                        | 1869 ± 107                                    |
| 20:1      | 12.0 ± 1.21       | 19.0 ± 4.59                        | 13.8 ± 1.06                                   |
| 24:1      | 14.2 ± 1.49       | 19.6 ± 3.58                        | 14.2 ± 0.74                                   |
| MUFA      | 1815 ± 31.1       | 2880 ± 110*                        | 2169 ± 25.3                                   |
| 18:2n-6   | 1742 ± 127        | 1778 ± 237                         | 1532 ± 91.6                                   |
| 20:4n-6   | 376 ± 40.1        | 439 ± 71.9                         | 430 ± 22.1                                    |
| 20:3n-6   | 82.7 ± 8.01       | 137 ± 18.2*                        | 92.5 ± 7.39                                   |
| 20:2n-6   | 16.1 ± 2.80       | 17.0 ± 1.89                        | 12.8 ± 0.97                                   |
| 22:5n-6   | 6.26 ± 0.66       | 8.14 ± 1.32                        | 6.94 ± 0.46                                   |
| 22:4n-6   | 10.7 ± 1.65       | 13.8 ± 2.23                        | 10.3 ± 0.65                                   |
| PUFAn-6   | 2234 ± 28.9       | 2393 ± 53.8                        | 2084 ± 19.1                                   |
| 18:3n-3   | 19.2 ± 2.26       | 42.5 ± 10.9*                       | 21.9 ± 2.41                                   |
| 20:5n-3   | 59.1 ± 7.34       | 72.2 ± 19.2                        | 60.0 ± 6.04                                   |
| 20:4n-3   | 8.02 ± 1.08       | 11.6 ± 1.71                        | 6.78 ± 0.79                                   |
| 22:6n-3   | 96.0 ± 13.1       | 83.7 ± 11.7                        | 106 ± 7.95                                    |
| 22:5n-3   | 26.5 ± 2.91       | 34.0 ± 5.65                        | 25.2 ± 1.63                                   |
| PUFAn-3   | 209 ± 5.02        | 244 ± 9.20                         | 220 ± 3.17                                    |

Data are presented as mean ± SEM

* p < 0.01; # p < 0.05 indicates a statistically significant difference compared to controls

studied groups of patients. We found strong positive correlations between CPOA2H and serum TAG in obese subjects and controls (Table 5). We also found positive correlations between CPOA2H and serum cholesterol in both groups of obese patients (Table 5).

Discussion

The FA profile in human serum is an established determinant of metabolic and cardiovascular risk [15]. A recent identification of CFA in human adipose tissue and blood [8] stimulated questions about their physiological role. We recently found CPOA2H in the serum of patients with obesity, a disease associated with dyslipidemia, inflammation and increased cardiovascular risk. Consequently, we decided to compare the serum concentrations of this FA in obese subjects and non-obese controls, and searched for associations between this parameter and selected markers of metabolic disorders. In addition, our study included individuals with CKD, a disease which is also associated with various lipid disorders and increased cardiovascular risk [16], but usually not with excess body weight. Obese women presented with higher CPOA2H levels than non-obese controls.
However, excess body weight did not seem to be a principal determinant of the serum concentration of this FA: although obese patients who had been subjected to a 3-month low-calorie diet still differed from non-obese controls in terms of BMI, they showed similar CPOA2H concentrations. In contrast, patients with CKD showed no significant difference from controls in terms of BMI, despite significantly higher serum CPOA2H levels. Lastly, we found no significant correlation between serum CPOA2H and BMI.

Since statistically significant correlations were found between serum CPOA2H and TAG levels, one can speculate that CPOA2H interacts with the endogenous synthesis of lipids—for instance, by influencing transcription factors involved in this process, as reported previously for other FA [17–19]. However, this hypothesis must be verified empirically, for example, by treating lipogenic cells with this FA. Importantly, the correlation between serum levels of CPOA2H and TAG may also reflect dietary intake of this FA with high-fat foods. Caligiani et al. recently reported the presence of an 18-carbon CFA in cow’s milk and dairy products [20]. In our previous study, we found CPOA2H in the TAG fraction of human blood [8], which suggests that this FA may originate from chylomicrons transporting ingested lipids. This hypothesis is also supported by the fact that obese individuals subjected to a 3-month low-calorie (low-lipid) diet presented with significantly lower serum levels of CPOA2H. Furthermore, the findings presented here are consistent with the results of our previous study [8], in which we found decreased CPOA2H levels in the adipose tissue of rats that had been provided 50 % of the total amount of food consumed by the controls for a period of 1 month. The fact that this FA has been found in certain high-fat foods commonly consumed in our country also supports this hypothesis, although we should note that the dietary origin of CPOA2H in the serum of patients is speculation on our part. Interestingly, patients with CKD—albeit without obesity—presented with high concentrations of CPOA2H. The diet recommended in CKD, however, is not rich in fat (Table 1). Therefore, high serum concentrations of CPOA2H in CKD patients seem to be associated rather with increased serum levels of TAG.

The relevance of altered serum concentrations of CPOAH2 remains unclear. Given the positive correlations between concentrations of this FA, TAG and cholesterol, as well as the elevated levels found in both obese

### Table 3  Selected characteristics of the study participants

| Test                        | Control (n = 22) | Obese patients (n = 10) | Obese patients after diet (n = 29) | Patients with chronic kidney disease (n = 15) |
|-----------------------------|-----------------|-------------------------|-----------------------------------|---------------------------------------------|
| Age (years)                 | 35.6 ± 2.62     | 46.4 ± 3.52             | 40.6 ± 1.75                       | 55.1 ± 3.74*                               |
| BMI (kg/m²)                 | 22.6 ± 0.67     | 43.3 ± 1.88*            | 40.7 ± 1.01*                      | 26.5 ± 1.35*                               |
| Albumin (g/L)               | 41.4 ± 0.74     | 40.0 ± 1.37             | 37.0 ± 0.93                       | 39.6 ± 1.38*                               |
| CRP (mg/L)                  | 0.75 ± 0.16     | 11.8 ± 3.21*            | 5.71 ± 0.79*                      | 4.72 ± 0.88*                               |
| Total cholesterol (mg/dL)   | 183 ± 5.42      | 188 ± 13.4              | 184 ± 7.92                        | 227 ± 10.1*                                |
| Triacylglycerols (mg/dL)    | 72.8 ± 9.06     | 180 ± 24.1*             | 122 ± 8.20*                       | 145 ± 17.8*                                |

Data are presented as mean ± SEM

*p < 0.01 indicates statistically significant difference compared to controls

### Table 4  Cyclopropanoic acid 2-hexyl content in commonly consumed high-fat foods

| Food                      | Porcine fat (µg/g) | Chicken fat (µg/g) | Trout fat (µg/g) | Cow’s milk (µmol/L) | Rapeseed oil |
|---------------------------|--------------------|--------------------|------------------|---------------------|--------------|
| Cyclopropanoic acid 2-hexyl content | 12.6               | 5.53               | 3.01             | 19.6                | nd           |
Table 5 Correlation coefficients between serum concentrations of cyclopropanoic acid 2-hexyl and selected biochemical and anthropometric parameters

| Parameter            | Controls   | Obese patients | Obese patients after diet | Patients with chronic kidney disease |
|----------------------|------------|----------------|---------------------------|--------------------------------------|
| Age                  | 0.40       | 0.37           | 0.18                      | 0.47                                 |
| BMI                  | 0.28       | -0.30          | -0.01                     | 0.16                                 |
| Albumin              | -0.01      | 0.47           | 0.16                      | 0.16                                 |
| CRP                  | -0.01      | -0.36          | 0.05                      | 0.06                                 |
| Total cholesterol    | 0.29       | 0.71*          | 0.47*                     | 0.01                                 |
| Triacylglycerols     | 0.66*      | 0.72*          | 0.71*                     | 0.40                                 |

* p < 0.01 indicates statistical significance

individuals and patients with kidney disease, we can speculate that CPOAH2 negatively affect the cellular metabolism of lipids. However, elevated levels of CPOA2H in these groups of patients may also represent an adaptive response. In vitro studies of hepatocytes and adipose tissue cells are needed to answer this question.

Conclusions

This study showed that hypertriglyceridemia observed during the course of diseases such as CKD and obesity is associated with an increase in serum concentration of CPOA2H. Future studies should elucidate whether this uncommon FA may influence cellular metabolism in humans.

Acknowledgments This study was supported by the Ministry of Science and Higher Education of the Republic of Poland, with the quality-promoting subsidy under the Leading National Research Centre (KNOW) program for the years 2012–2017, National Science Centre of Poland (Grant No. NCN 2013/11/B/N25/00118), and Medical University of Gdansk (Grant No. ST-40, ST-89).

Compliance with Ethical Standards

Conflict of interest We declare no conflict of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Grogan DW, Cronan JE Jr (1997) Cyclopropane ring formation in membrane lipids of bacteria. Microbiol Mol Biol Rev 61:429–441
2. Rahman MD, Ziering DL, Mannarelli SJ, Swartz KL, Huang DS, Pascal RA Jr (1988) Effects of sulfur-containing analogues of stearic acid on growth and fatty acid biosynthesis in the protozoan Crithidia fasciculata. J Med Chem 31:1656–1659
3. Yu XH, Rawat R, Shanklin J (2011) Characterization and analysis of the cotton cyclopropane fatty acid synthase family and their contribution to cyclopropane fatty acid synthesis. BMC Plant Biol 11:97
4. Yu XH, Prakash RR, Sweet M, Shanklin J (2014) Coexpressing Escherichia coli cyclopropane synthase with Sterculia foetida Lysosphosphatic acid acyltransferase enhances cyclopropane fatty acid accumulation. Plant Physiol 164:455–465
5. Carballera NM, Montano N, Vicente J, Rodriguez AD (2007) Novel cyclopropane fatty acid fats from the phospholipids of the Caribbean sponge Pseudospongosorites suberitoides. Lipids 42:519–524
6. Rob T, Ogi T, Maarist W, Taira J, Ueda K (2011) Isolation of C(1)(1) compounds and a cyclopropane fatty acid from an Okinawan ascidian, Diplomysa sp. Molecules 16:9972–9982
7. Sakurada K, Iwase H, Takatori T, Nagao M, Nakajima M, Nijima H, Matsuda Y, Kobayashi M (1999) Identification of cis-9,10-methylenehexadecanoic acid in sub mitigochondrial particles of bovine heart. Biochim Biophys Acta 1437:214–222
8. Siedzinski T, Mika A, Stepnowski P, Proczko-Markuszewska M, Kaska L, Stefaniak T, Swierczynski J (2013) Identification of cyclopropanoic acid 2-hexyl in human adipose tissue and serum. Lipids 48:839–848
9. Dong L, Vecchio AJ, Sharma NP, Jurban BJ, Malikowski MG, Smith WL (2011) Human cyclooxygenase-2 is a sequence homodimer that functions as a conformational heterodimer. J Biol Chem 286:19035–19046
10. Sakurada K, Iwase H, Kobayashi M, Uemura H, Nakaya H, Ikegaya H, Yoshida K (2000) cis-9,10-Methylenehexadecanoic acid inhibits contractility and actomyosin ATPase activity of guinea pig myocardium. Biochem Biophys Res Commun 274:533–536
11. Kanno T, Yamamoto H, Yaguchi T, Hi R, Mukasa T, Fujikawa H, Nagata T, Yamamoto S, Tanaka A, Nishizaki T (2006) The linoleic acid derivative DCP-LA selectively activates PKC-epsilon, possibly binding to the phosphatidylinositol binding site. J Lipid Res 47:1146–1156
12. Kadegowda AK, Burns TA, Pratt SL, Duckett SK (2013) Inhibition of steroyl-CoA desaturase 1 reduces lipogenesis in primary bovine adipocytes. Lipids 48:967–976
13. Huang JD, Amaral J, Lee JW, Larroyoz IM, Rodriguez IR (2012) Stercric acid antagonizes 7-ketocholesterol-mediated inflammation and inhibits choroidal neovascularization. Biochim Biophys Acta 1821:637–646
14. Bao X, Katz S, Pollard M, Ohlrogge J (2002) Carbocyclic fatty acids in plants: biochemical and molecular genetic characterization of cyclopropane fatty acid synthesis of Sterculia foetida. Proc Natl Acad Sci USA 99:7172–7177
15. Aro A (2003) Fatty acid composition of serum lipids: is this marker of fat intake still relevant for identifying metabolic and cardiovascular disorders? Nutr Metab Cardiovasc Dis 13:253–255
16. Trevisan R, Dodesini AR, Lepore G (2006) Lipids and renal disease. J Am Soc Nephrol 17:S145–S147
17. Masi LN, Rodrigues AC, Curi R (2013) Fatty acids regulation of inflammatory and metabolic genes. Curr Opin Clin Nutr Metab Care 16:418–424
18. Fei J, Cook C, Santanam N (2012) Omega-6 lipids regulate PPAR turnover via reciprocal switch between PGC-1 alpha and ubiquitination. Atherosclerosis 222:395–401
19. Yang ZH, Miyahara H, Hatanaka A (2011) Chronic administration of palmitoleic acid reduces insulin resistance and hepatic lipid accumulation in KK-Ay Mice with genetic type 2 diabetes. Lipids Health Dis 10:120
20. Caligiani A, Marseglia A, Palla G (2014) An overview on the presence of cyclopropane fatty acids in milk and dairy products. J Agric Food Chem 62:7828–7832
21. Folch J, Lees M, Sloane Stanley GH (1957) A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 226:497–509